Strategic Trial for the Prevention of Progression of Overt Diabetic Kidney Disease by GLP-1receptor agonists and SGLT2 inhibitors in Okinawa

Trial Profile

Strategic Trial for the Prevention of Progression of Overt Diabetic Kidney Disease by GLP-1receptor agonists and SGLT2 inhibitors in Okinawa

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs Empagliflozin (Primary) ; Liraglutide (Primary)
  • Indications Diabetic nephropathies; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms STOPPER
  • Most Recent Events

    • 04 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top